Sort   by:  
 Page size 
GenomicsSynthetic lethality of paclitaxel and afatinib in MDA-MB-231 cells
Synthetic lethality of paclitaxel and afatinib in MDA-MB-231 cells
PRJNA821481 | ENA
GenomicsWhole exome sequencing (WES) on available pre- and post-afatinib tumor biopsies and normal tissue.
To determine survival in afatinib-treated patients after treatment with first-generation EGFR tyrosine kinase inhibitors (TKIs) and to study resistance mechanisms in afatinib-resistant tumors.
PRJEB21459 | ENA
GenomicsWhole exome sequencing (WES) and pathway analysis was performed on available pre- and post-afatinib tumor biopsies and normal tissue.
To determine survival in afatinib-treated patients after treatment with first-generation EGFR tyrosine kinase inhibitors (TKIs) and to study resistance mechanisms in afatinib-resistant tumors.
PRJEB22736 | ENA
GenomicsRomidepsin and afatinib combination treatment induce synergistic anti-lymphoma effect in CTCL
Romidepsin and afatinib combination treatment induce synergistic anti-lymphoma effect in CTCL
PRJNA994103 | ENA
TranscriptomicsRNA-seq of FGFR2 fusion+ ICC cell lines (ICC21 and ICC10-6) treated with Infigratinib or/and Afatinib against untreated control
Genomic alterations that activate Fibroblast Growth Factor Receptor 2 (FGFR2) are common in intrahepatic cholangiocarcinoma (ICC), a deadly bile duct malignancy. FGFR kinase inhibitors (FGFRi) have shown promising efficacy against FGFR2+ ICC in clinical trials, leading to the regulatory approval of ...
ORGANISM(S): Homo sapiens 
2024-03-21 | E-MTAB-11324 | biostudies-arrayexpress
ClinicalAfatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer
This is a multi-center open-label proof-of-concept study consisting of two parts: PART A - a phase I dose-finding study (3 + 3 classical design) evaluating the RP2D of afatinib in combination with selumetinib in KRASm NSCLC; and PART B - a randomized phase II study investigating the progression free...
2190517 | ecrin-mdr-crc
TranscriptomicsEstablishment of Afatinib-Resistant Non-Small Cell Lung Cancer Cells Derived from Tumor Xenograft Model [Afatinib treatment]
This experiment aimed to indentify signifcant expression genes in afatinib-resistant HCC827 cell lines under different treatment conditions. All the expression profiles of BR16-1 and BR16-2 cells were comapared to parental HCC827 cells.
ORGANISM(S): Homo sapiens 
2015-12-01 | GSE75467 | GEO
GenomicsEffects of EGF, cetuximab, trastuzumab and afatinib on gene expression in gastric cancer cell lines
Effects of EGF, cetuximab, trastuzumab and afatinib on gene expression in gastric cancer cell lines
PRJNA593206 | ENA
UnknownClinical Pharmacokinetics and Pharmacodynamics of Afatinib.
Not available
S-EPMC5315738 | biostudies-literature
TranscriptomicsSynthetic lethality of paclitaxel and afatinib in MDA-MB-231 cells
We performed mono- or combo-therapies of paclitaxel and afatinib and performed RNA-seq to compare the perturbed transcriptome in MDA-MB-231 cells
ORGANISM(S): Homo sapiens 
2022-04-02 | GSE199779 | GEO
Sort   by:  
 Page size